Neurelis vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Neuroscience pharma commercializing VALTOCO (diazepam nasal spray) for seizure clusters. ~$295-300M estimated net sales in 2025; 30%+ EBITDA margin; no bank debt.
About
Neurelis is a private neuroscience-focused pharmaceutical company dedicated to developing and commercializing therapies for epilepsy and neurological disorders. Its lead commercial product, VALTOCO (diazepam nasal spray), is an FDA-approved treatment for acute seizure clusters in patients aged two and older — a label expansion to children ages two to five was approved in April 2025. The company reported estimated net sales of $295–300 million for 2025, more than doubling 2024 revenue, with an EBITDA margin exceeding 30% and a debt-free balance sheet holding $175M+ in cash. VALTOCO''s Orange Book patent portfolio now includes six listed patents, extending exclusivity to October 2032. Neurelis is using this commercial momentum to advance its CNS pipeline and pursue additional products.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.